Beeline Therapeutics
Buffalo
About Beeline Therapeutics
Beeline is an early-stage preclinical cell therapy company developing the next generation of immune cell therapies for immune-mediated human disease, particularly diseases which result from the patient's own immune cells attacking healthy tissue. We are genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo and induce tolerance. In particular, we are re-engineering Regulatory T cells (Tregs) to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins, and combining enhanced Treg function with antigen specificity via targeting receptors for improved localization.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Funding stage: Seed
- Last round: Seed (Apr 2019)
- Website: beelinetherapeutics.com
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/beeline-therapeutics-1884314 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.